Phase 1 study of safety, pharmacokinetics, and antiviral activity of SARS‐CoV‐2 neutralizing monoclonal antibody ABBV‐47D11 in patients with COVID‐19

por Shebley, Mohamad, Wang, Stanley, Ali, Izna, Krishnan, Preethi, Tripathi, Rakesh, Reardon, Joseph M., Cafardi, John, Rahav, Galia, Caraco, Yoseph, Slim, Jihad, Al Akhrass, Fadi, Yu, Mengjia, Hu, Yiran, Ferreira, Rosa De Abreu, Alami, Negar N.
Publicado 2022